Regeneron Pharmaceuticals Inc (REGN)
Pretax margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 4,199,300 | 4,376,400 | 4,775,400 | 4,655,700 | 4,858,800 | 6,037,500 | 6,344,300 | 9,133,900 | 9,325,800 | 8,047,000 | 7,228,700 | 4,394,800 | 3,810,400 | 3,475,600 | 3,245,800 | 2,551,600 | 2,429,100 | 2,215,500 | 2,082,900 | 2,514,300 |
Revenue (ttm) | US$ in thousands | 13,044,200 | 13,025,200 | 12,601,200 | 12,306,100 | 12,113,500 | 13,654,100 | 14,171,800 | 16,451,800 | 16,014,400 | 13,499,700 | 12,328,800 | 9,147,000 | 8,455,000 | 8,201,600 | 7,974,500 | 7,957,900 | 7,839,900 | 7,598,200 | 7,213,600 | 6,889,000 |
Pretax margin | 32.19% | 33.60% | 37.90% | 37.83% | 40.11% | 44.22% | 44.77% | 55.52% | 58.23% | 59.61% | 58.63% | 48.05% | 45.07% | 42.38% | 40.70% | 32.06% | 30.98% | 29.16% | 28.87% | 36.50% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $4,199,300K ÷ $13,044,200K
= 32.19%
Regeneron Pharmaceuticals, Inc. has shown a gradual decline in its pretax margin over the past eight quarters. The pretax margin was highest in Q1 2022 at 55.33% but has since experienced a downward trend, reaching its lowest value of 32.01% in Q4 2023. This decrease may indicate inefficiencies in cost management or a decrease in revenue relative to expenses. The declining pretax margin suggests that Regeneron Pharmaceuticals, Inc. may need to focus on improving operational efficiency and cost control measures to enhance profitability.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Regeneron Pharmaceuticals Inc
REGN
32.19%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
15.07%
Amphastar P
AMPH
26.28%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-257.26%
Biomarin Pharmaceutical Inc
BMRN
9.72%
Bristol-Myers Squibb Company
BMY
18.72%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%